Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients.

Lindsay R, Nieves J, Henneman E, Shen V, Cosman F

The Journal of clinical endocrinology and metabolism1 Dec 1993Cited by 54 (Europe PMC)

PMID8263137DOI10.1210/jcem.77.6.8263137PepBankPUB-08263137

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialPharmacokinetics
In estrogen-treated osteoporotic patients, circulating hPTH(1-34) peaked at 30 min, averaging 10 times normal.
In plain wordsIn estrogen-treated patients with osteoporosis, injected hPTH peaked in blood at 30 minutes, averaging 10 times normal.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCirculating peptide peak
Study
n = 11
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Measurements
Time to peak
30 min
hPTH-(1-34)
Peak circulating hPTH-(1-34) level
10 times normal
hPTH-(1-34), average
Source sentences
Summary
Increments in circulating hPTH-(1-34) were brisk, peaking at 30 min, with variable peak levels averaging 10 times normal.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313701
02HumanNon-randomized trialPharmacokinetics
In estrogen-treated osteoporotic patients, hPTH(1-34) clearance followed an exponential pattern with a mean half-life of 75 min.
In plain wordsIn estrogen-treated patients with osteoporosis, injected hPTH had a mean blood half-life of 75 minutes.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableCirculating peptide half-life
Study
n = 11
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Measurements
Half-life
75 min
hPTH-(1-34)
Source sentences
Summary
Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313702
03HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, hPTH(1-34) suppressed serum PTH-(1-84) to about 65% of baseline for 4 h.
In plain wordsIn estrogen-treated patients with osteoporosis, hPTH reduced natural full-length PTH to about 65% of baseline for 4 hours.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum PTH-(1-84)
Study
n = 11
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Measurements
Serum PTH-(1-84) as share of basal value
≈ 65 % of basal value
after hPTH-(1-34) administration, for 4 h
Source sentences
Summary
Peptide administration was followed by an immediate decline in serum concentrations of PTH-(1-84), which remained suppressed at about 65% of the basal value for the duration of the study (4 h).
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313703
04HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, serum calcium increased at 120 min after hPTH(1-34), after serum PTH-(1-84) declined.
In plain wordsIn estrogen-treated patients with osteoporosis, blood calcium increased at 120 minutes after hPTH, after natural full-length PTH declined.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium
Study
n = 11
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Source sentences
Summary
Serum calcium did not increase until 120 min, thus occurring after the diminution in PTH-(1-84).
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313704
05HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, serum phosphorus declined promptly after hPTH(1-34).
In plain wordsIn estrogen-treated patients with osteoporosis, blood phosphorus decreased promptly after hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum phosphorus
Study
n = 11
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Source sentences
Summary
Serum phosphorus declined promptly as urinary phosphate excretion increased.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313705
06HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, urinary phosphate excretion increased after hPTH(1-34).
In plain wordsIn estrogen-treated patients with osteoporosis, urinary phosphate excretion increased after hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary phosphate excretion
Study
n = 11
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Source sentences
Summary
Serum phosphorus declined promptly as urinary phosphate excretion increased.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313706
07HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, urinary calcium excretion showed no clear change after hPTH(1-34).
In plain wordsIn estrogen-treated patients with osteoporosis, urinary calcium excretion showed no clear change after hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary calcium excretion
Study
n = 11
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Source sentences
Summary
There were no clear changes in urinary calcium excretion, but urinary cAMP excretion increased within 120 min.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313707
08HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, urinary cAMP excretion increased within 120 min after hPTH(1-34).
In plain wordsIn estrogen-treated patients with osteoporosis, urinary cAMP increased within 120 minutes after hPTH.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUrinary cAMP excretion
Study
n = 11
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Source sentences
Summary
There were no clear changes in urinary calcium excretion, but urinary cAMP excretion increased within 120 min.
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313708
09HumanNon-randomized trialActivity measurement
In estrogen-treated osteoporotic patients, serum 1,25-dihydroxyvitamin D increased in 9 of 11 patients, with mean levels approximately 30% above baseline.
In plain wordsIn estrogen-treated patients with osteoporosis, active vitamin D increased in 9 of 11 patients, with mean levels approximately 30% above baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum 1,25-dihydroxyvitamin D
Study
n = 11
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
25 micrograms (400 U) · subcutaneousAs given in this study (human).
Measurements
Mean serum 1,25-dihydroxyvitamin D increase vs baseline
≈ 30%
mean, after 90 min
Patients with increased serum 1,25-dihydroxyvitamin D
9 of 11 patients
hPTH-(1-34)
Source sentences
Summary
In 9 of 11 patients, the serum concentration of 1,25-dihydroxyvitamin D increased, with mean levels increasing progressively after 90 min to approximately 30% above baseline (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.
Report a problemFND-0826313709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms